We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Celtic Pharma Announces Results of a Phase III Program Evaluating XERECEPT® in Brain Tumors

News   Jun 08, 2009

 
Celtic Pharma Announces Results of a Phase III Program Evaluating XERECEPT® in Brain Tumors
 
 
Advertisement
 

RELATED ARTICLES

Team Uncovers New Mechanism of Action Against SARS-CoV-2 by Remdesivir

News

Researchers have discovered a novel, second mechanism of action by the antiviral drug remdesivir against SARS-CoV-2, according to findings published in the Journal of Biological Chemistry.

READ MORE

Exercise Hormone May Modulate Genes Associated With SARS-CoV-2

News

A study conducted by researchers at São Paulo State University (UNESP) suggests that irisin, a hormone secreted from muscles in response to exercise, could have a therapeutic effect on COVID-19 patients.

READ MORE

Study Investigates Racial Disparities in Clinical Trial Recruitment

News

Scientists are increasingly turning to electronic-based recruitment methods to encourage participation in clinical trials. Little is known about how this use of technology compares to more traditional clinical trial recruitment strategies, and some researchers worry that an overreliance on technology has the potential to exclude an eligible and interested diverse participant population.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE